My group's primary focus is translational and technology-oriented research on protein-based biomolecules and bio-pharmaceuticals with industrial applications. My team is comprised of researchers with the background of biotechnology, industrial microbiology, molecular biology, bioprocessing, fermentation and biochemical engineering. Our major lab projects are:

1. Vaccine discovery and bioprocess development: We employ reverse vaccinology-linked bioprocess technologies for design of vaccine antigens against bacterial and viral pathogens,  process development and, their scale-up, to establish proof-of-concept for the technology.  
2. Monoclonal antibody development (mAb): We utilise a CHO cell-based bioprocess platform for the production of industry-compatible therapeutic monoclonal antibodies (mAbs) through the establishment of stable cell lines and bioreactor-based scale-up. We are also investigating novel protein/antibody-drug conjugates for targeted cancer therapy to improve therapeutic efficacy and specificity.
3. Strain engineering and biopharma cell bank development in GMP conditions: We possess cutting-edge facilities for the development of cGMP-compliant cell banks and vectors utilised in the early development and biomanufacturing of biopharmaceuticals, including vaccines, biotherapeutics, fermentation-based APIs, industrial enzymes and disgnostics.

•    Jitender, Vikram Kumar, B., Singh, S., Verma, G., Kumar, R., Mishra, P. M., Kumar, S., Nagaraj, S. K., Nag, J., Joy, C. M., Nikam, B., Singh, D., Pooja, Kalidas, N., Singh, S., Mumtaz, Bhardwaj, A. K., Mankotia, D. S., Ringe, R. P., … Mishra, R. P. N. (2024). Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster. Vaccine, 42(20), 126099.
•    Singh, S., Kumar, B. V., Jitender, Mishra, P. M., Verma, G., Kumar, S., Pandit, S., Kumar, R., Ringe, R. P., Tripathi, S., Gupta, N., & Mishra, R. P. N. (2024). Scalable bioprocess for high-yield production of SARS-CoV-2 trimeric spike protein-based immunogen (IMT-CVAX) using suspension CHO cells. Process Biochemistry, 147, 332–346. 
•    Jitender, Vikram Kumar, B., Singh, S., Verma, G., Kumar, R., Mishra, P. M., Kumar, S., Nagaraj, S. K., Nag, J., Joy, C. M., Nikam, B., Singh, D., Pooja, Kalidas, N., Singh, S., Mumtaz, Bhardwaj, A. K., Mankotia, D. S., Ringe, R. P., … Mishra, R. P. N (2023). A broadly protective CHO cell expressed recombinant spike protein subunit vaccine (IMT-CVAX) against SARS-CoV-2. BioRxiV https://doi.org/10.1101/2023.04.03.534161  
•    Nandal, J., Mihooliya, K. N., Verma, H., Kalidas, N., Ashish, F., Mishra, R. P. N., & Sahoo, D. K. (2022). Evaluation of physicochemical and functional similarity of a new CHO derived anti-EGFR antibody P-mAb to its reference medicinal product. Artificial Cells, Nanomedicine, and Biotechnology, 50 (1), 17–28. 
•    Bagnoli, F., Fontana, M. R., Soldaini, E., Mishra, R. P. N., Fiaschi, L., Cartocci, E., Nardi-Dei, V., Ruggiero, P., Nosari, S., De Falco, M. G., Lofano, G., Marchi, S., Galletti, B., Mariotti, P., Bacconi, M., Torre, A., Maccari, S., Scarselli, M., Rinaudo, C. D., … Grandi, G. (2015). Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus. Proceedings of the National Academy of Sciences, USA 112(12), 3680–3685. 
•    Mishra, R. P. N., Mariotti, P., Fiaschi, L., Nosari, S., Maccari, S., Liberatori, S., Fontana, M. R., Pezzicoli, A., De Falco, M. G., Falugi, F., Altindis, E., Serruto, D., Grandi, G., & Bagnoli, F. (2012). Staphylococcus aureus FhuD2 Is Involved in the Early Phase of Staphylococcal Dissemination and Generates Protective Immunity in Mice. Journal of Infectious Diseases, 206(7), 1041–1049. 
•    Mishra, R. P. N., Oviedo-Orta, E., Prachi, P., Rappuoli, R., & Bagnoli, F. (2012). Vaccines and antibiotic resistance. Current Opinion in Microbiology, 15(5), 596–602. 
•    Mariotti P, Malito E, Biancucci M, Lo Surdo P, Mishra R.P.N…….Bagnoli F.., (2013) Structural and functional characterization of the Staphylococcus aureus virulence factor and vaccine candidate FhuD2. Biochemical Journal 449:683–693.
 

•    Process for recombinant production and purification of SARS-CoV-2 spike protein. WO2024052938A1
•    Recombinant protein for management of SARS-CoV-2 infection. 202211030140 Compositions for immunising against Staphylococcus aureus. US9205142B2, CN109248313B, MX363222B, EP2510947B, ZA201302878B, JP7109412B2,  CA2758490C, SI2510947T1 , SG10201404076TA, PL2510947T3.
•    Immunogenic composition useful for immunization against Staphylococcus aureus, its preparation method and pharmaceutical composition. BRPI1013780B8.  
•    Codon optimized polynucleotide for high level expression of CRM197. US10280409B2, EP3221339B1, CA2968491C, ZA201703150B, JP7042305B2, SA517381488B1AU2015348922B2, BR112017010718B1
•    Immunogenic composition comprising fragmented Vi capsular polysaccharide-protein conjugate.  2201741022224